EV102 (Enveric Biosciences)

**EV102** is an investigational topical cannabidiol-based prescription drug candidate developed by Enveric Biosciences for the treatment of radiodermatitis, a radiation therapy-associated skin toxicity in cancer patients. The product was designed for topical application to reduce dermatitis severity, erythema, and symptom duration; preclinical rodent data reported meaningful reductions in redness and overall dermatitis severity. EV102 appears to be a cannabinoid-based topical formulation whose therapeutic rationale is local anti-inflammatory and skin-protective activity of cannabidiol, although a precise validated molecular mechanism for the product itself has not been publicly defined. The program was planned to advance into early clinical testing but has subsequently been reported as discontinued.

Other names

topical cannabidiol radiodermatitis drug candidate